UP!

BRKR $39.25   View long term graphs

Bruker
Type
Public
Traded as NASDAQ: BRKR
Founded 1960 in Germany
Founder Professor Günther Laukien
Headquarters Billerica, Massachusetts, USA
Key people
Dr. Frank Laukien, President & CEO; William Knight, COO
Revenue IncreaseUS$ 1.62 billion (2015)[1]
Number of employees
6000
Website www.bruker.com

Bruker Corporation is a manufacturer of scientific instruments for molecular and materials research, as well as for industrial and applied analysis. It is headquartered in Billerica, Massachusetts and is the publicly traded parent company of Bruker Scientific Instruments (Bruker AXS, Bruker BioSpin, Bruker Daltonics and Bruker Optics) and Bruker Energy & Supercon Technologies (BEST) divisions.

In April 2010, Bruker created a Chemical Analysis Division (headquartered in Fremont, CA) under the Bruker Daltonics subsidiary. This division contains three former Varian product lines: ICPMS systems, laboratory gas chromatography (GC), and GC-triple quadrupole mass spectrometer (originally designed by Bear Instruments and acquired by Varian in 2001).

In 2012 it sponsored the Fritz Feigl Prize, and since 1999 the company has also sponsored the Günther Laukien Prize.

The company was founded on September 7, 1960, in Karlsruhe, Germany as Bruker-Physik AG by five people, one of them being Günther Laukien, who was a professor at the University of Karlsruhe at the time. The name Bruker originates from co-founder Emil Bruker, as Günther Laukien himself was formally not allowed to commercialize his research whilst being a professor. Bruker produced Nuclear Magnetic Resonance Spectroscopy (NMR) and EMR spectroscopy equipment then. In the early 1960s, the company had around 60 employees and was growing rapidly. One of the early success products was the HFX 90 NMR spectroscopy system, with three independent channels and which was also the first NRM system using only semiconductor transistors. In 1969, Bruker launched the first commercial Fourier transform NMR spectroscopy system (FT-NMR) and in the 1970s the company was the first to commercialize a superconducting FT-NMR. Later, the company would expand their product range with MRI, FTIR and FT-Raman spectrometers and with mass spectrometers.

In 1968, Bruker shipped NMR systems to Yale University in Connecticut. After that, demand from the United States grew, so Bruker opened an office in Elmsford, New York which marked the start of their US activities. In 2008 after a corporate reorganization lasting 8 years, all divisions were merged in a unified Bruker Corporation.

Günther Laukien died in 1997, his son Frank D. Laukien, is currently the CEO of Bruker. His son Jörg C. Laukien, also works for the company. His son Dirk D. Laukien is a former company executive.

In 1964, the company bought the NMR division of the Swiss Trüb-Täuber.

Bruker made several offers to take over its supplier Oxford Instruments during the 1970s, but after almost a decade of negotiations, an acquisition was eventually rejected by Oxford Instruments.

In 1997, the analytical X-ray division of Siemens was acquired by Bruker.

In 2010 Bruker bought 3 product lines from Agilent, which Agilent had acquired from Varian. These included mass spectrometry and gas chromatography instruments. They have since divested these products to Scion Instruments with the exception of the triple quadrupole

In 2012 Bruker bought parts of Carestream Health, including their in-vivo imaging portfolio and related aspects.

Bruker develops and delivers a wide variety of professional and scientific analysis devices including:

Bruker products are used globally in a variety of situations. The National High Magnetic Field Laboratory at Florida State University selected Bruker to build the world's first 21.0 tesla FT-ICR MS.

The Total Carbon Column Observing Network uses high resolution FT spectrometers made by Bruker to measure various greenhouse gases across the globe.

In May, 2004, Frost & Sullivan selected the Company's Bruker Daltonics subsidiary for their 2004 Product Line Innovation Award for the Life Sciences. Bruker Daltonics received this award for its innovative development of sophisticated mass spectrometers.

News

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2020 2021-03-25 Future report Set alerts
Q3 2020 2020-10-29 Future report Set alerts
Q2 2020 2020-08-03 0.21 0.16
Q1 2020 2020-05-06 0.14 0.07
Q4 2019 2020-02-18 0.53 0.44
Q3 2019 2019-10-31 0.43 0.39
Q2 2019 2019-08-01 0.33 0.23
Q1 2019 2019-05-02 0.28 0.20
Q4 2018 2019-02-11 0.54 0.50
Q3 2018 2018-11-01 0.37 0.28

Ratings

2016-06-10 Reiterated Rating Jefferies Group Buy
2016-06-01 Initiated Coverage Deutsche Bank Hold
2016-06-01 Initiated Coverage Deutsche Bank AG Hold
2016-05-07 Reiterated Rating Jefferies Group Buy $28.00 to $30.00
2016-05-05 Boost Price Target Barclays Overweight $30.00 to $32.00
2016-05-05 Boost Price Target Leerink Swann Market Perform $27.00 to $28.00
2016-05-05 Boost Price Target Mizuho Neutral $22.00 to $28.00
2016-05-05 Downgrade BTIG Research Buy to Neutral
2016-05-05 Boost Price Target Barclays PLC Overweight $30.00 to $32.00
2016-04-05 Downgrade Bank of America Neutral to Underperform
2016-04-05 Downgrade Leerink Swann Outperform to Market Perform $27.00
2016-04-05 Downgrade Leerink Partner Outperform to Market Perform
2016-04-05 Downgrade Bank of America Corp. Neutral to Underperform
2016-03-23 Boost Price Target Goldman Sachs $21.00
2016-03-23 Boost Price Target Goldman Sachs Group Inc. $21.00
2016-03-14 Boost Price Target Stifel Nicolaus Buy $25.00 to $32.00
2016-03-01 Initiated Coverage Barclays Overweight $30.00
2016-02-22 Reiterated Rating BTIG Research Buy $27.00
2016-02-11 Reiterated Rating Jefferies Buy $25.00 to $28.00
2016-02-11 Reiterated Rating Leerink Swann Outperform $25.00 to $26.00
2016-02-11 Reiterated Rating Jefferies Group Buy $25.00 to $28.00
2016-02-11 Boost Price Target Goldman Sachs Sell $17.00 to $19.00
2016-02-11 Lower Price Target Evercore ISI Hold $25.00 to $23.50
2016-02-11 Reiterated Rating Deutsche Bank Hold $24.00 to $23.00
2016-02-11 Reiterated Rating BTIG Research Buy $27.00
2016-02-11 Reiterated Rating Cantor Fitzgerald Buy $27.00
2016-01-25 Upgrade Cantor Fitzgerald Hold to Buy $27.00
2016-01-07 Boost Price Target Cowen and Company $24.00
2016-01-06 Initiated Coverage Deutsche Bank Hold $24.00
2016-01-06 Initiated Coverage Avondale Partners Market Perform $26.00
2015-12-08 Boost Price Target Goldman Sachs $15.00 to $17.00
2015-11-24 Lower Price Target Goldman Sachs Sell $16.00 to $15.00
2015-11-12 Initiated Coverage Stifel Nicolaus Buy to Buy $24.00
2015-11-05 Reiterated Rating BTIG Research Buy $25.00
2015-11-05 Boost Price Target Leerink Swann Outperform $24.00 to $25.00
2015-11-05 Boost Price Target Cantor Fitzgerald Hold $22.00 to $23.00
2015-10-15 Lower Price Target Citigroup Inc. Neutral $22.00 to $20.00
2015-10-14 Reiterated Rating BTIG Research Buy $25.00
2015-10-06 Reiterated Rating BTIG Research Buy $25.00
2015-10-02 Lower Price Target Cowen and Company Market Perform $20.00 to $18.00
2015-09-17 Reiterated Rating BTIG Research Buy $25.00
2015-09-15 Initiated Coverage Morgan Stanley Equal to Equal Weight $21.00
2015-08-27 Initiated Coverage Maxim Group Hold $22.00
2015-08-26 Initiated Coverage Cantor Fitzgerald Hold $22.00
2015-08-20 Reiterated Rating BTIG Research Buy $25.00
2015-08-06 Reiterated Rating BTIG Research Buy $25.00
2015-06-22 Set Price Target Evercore ISI Hold $21.00
2015-05-23 Reiterated Rating Jefferies Group Buy $25.00
2015-05-21 Downgrade William Blair Outperform to Market Perform
2015-05-21 Downgrade Mizuho Buy to Neutral $22.00
2015-05-08 Reiterated Rating Cantor Fitzgerald Hold $22.00
2015-04-06 Upgrade Leerink Swann Market Perform to Outperform $21.00 to $24.00
2015-02-20 Reiterated Rating JPMorgan Chase & Co. Hold $22.00 to $20.00
2015-02-20 Reiterated Rating Jefferies Group Buy $26.00 to $25.00
2015-02-20 Reiterated Rating Citigroup Inc. Hold $22.00 to $21.00
2015-02-20 Set Price Target Cantor Fitzgerald Hold $22.00
2015-02-20 Reiterated Rating BTIG Research Buy $25.00
2015-02-20 Lower Price Target Mizuho Buy $25.00 to $22.00
2015-02-10 Downgrade Bank of America Buy to Neutral $21.00 to $20.00
2014-12-18 Downgrade Goldman Sachs Buy to Sell $21.00 to $15.00
2014-12-03 Initiated Coverage BTIG Research Buy
2014-11-07 Downgrade Citigroup Inc. Buy to Neutral $27.00 to $22.00
2014-11-07 Reiterated Rating Bank of America Buy $26.00 to $23.00
2014-11-07 Downgrade Cantor Fitzgerald Buy to Hold
2014-07-17 Initiated Coverage Citigroup Inc. Buy
2014-07-08 Downgrade ISI Group Buy to Neutral $25.50
2014-07-08 Downgrade Evercore ISI Buy to Neutral $25.50
2014-07-01 Boost Price Target Cowen and Company $25.00 to $27.50
2014-06-19 Upgrade Wells Fargo & Co. Market Perform to Outperform
2014-06-19 Upgrade Wells Fargo Market Perform to Outperform
2014-05-08 Lower Price Target Evercore ISI $24.50
2014-03-05 Boost Price Target Macquarie $23.00 to $28.00
2014-02-19 Boost Price Target Jefferies Group $24.00 to $27.00
2014-02-19 Boost Price Target Evercore ISI $23.50 to $24.50
2013-11-06 Initiated Coverage Morgan Stanley Overweight $23.00
2013-09-27 Initiated Maxim Group Buy $27
2013-09-27 Boost Price Target Goldman Sachs Buy $21.00 to $22.00
2013-09-26 Initiated Coverage Maxim Group Buy $27.00
2013-09-20 Initiated Coverage Cleveland Research Buy
2013-09-20 Downgrade Wells Fargo & Co. Outperform to Market Perform
2013-09-20 Downgrade Wells Fargo Outperform to Market Perform
2013-08-23 Reiterated Mizuho Buy $21 to $25
2013-05-22 Reiterated Mizuho Buy $18 to $21
2013-05-03 Reiterated ISI Group Buy $21.50 to $18.50
2013-02-19 Reiterated Cantor Fitzgerald Buy $18 to $21
2013-01-07 Upgrade ISI Group Neutral to Buy $15 to $19
2012-11-06 Reiterated Cantor Fitzgerald Buy $14 to $16
2012-07-25 Reiterated Mizuho Neutral $17 to $12
2012-07-12 Initiated Cantor Fitzgerald Buy $16
2011-08-04 Reiterated UBS Buy $23 to $21
2011-04-08 Downgrade Deutsche Bank Buy to Hold $23 to $23
2011-01-10 Upgrade UBS Neutral to Buy $17 to $21
2010-10-28 Reiterated JMP Securities Mkt Outperform $18 to $20
2010-10-11 Reiterated UBS Neutral $15 to $16
2016-06-10 Reiterated Rating Jefferies Group Buy
2016-06-01 Initiated Coverage Deutsche Bank Hold
2016-06-01 Initiated Coverage Deutsche Bank AG Hold
2016-05-07 Reiterated Rating Jefferies Group Buy $28.00 to $30.00
2016-05-05 Boost Price Target Barclays Overweight $30.00 to $32.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
LAUKIEN FRANK H CEO, President 22.49%  (37791386) BRKR /
LAUKIEN DIRK D 9.44%  (15862972) BRKR /
LAUKIEN JOERG C 9.05%  (15215769) BRKR /
WAGNER CHARLES F JR 0.06%  (99925) BRKR /
LINTON WILLIAM A 0.04%  (60801) BRKR /
Munch Mark Pres. Bruker Nano Inc. 0.03%  (58113) BRKR /
Srega Juergen Group President Bruker CALID 0.03%  (56713) BRKR /
KNISS RICHARD 0.03%  (44227) BRKR /
PACKER RICHARD A 0.03%  (43158) BRKR / TFX /
MATTACCHIONE ANTHONY L Sr VP, Corp Fin & Accounting 0.02%  (34726) BRKR /
Bachmann Thomas Werner President Bruker BioSpin Group 0.02%  (27700) BRKR /
WANGLER BERNHARD 0.01%  (20250) BRKR /
KELLER TONY WERNER 0.01%  (13340) BRKR /
Lenggenhager Rene President, BioSpin Group 0.01%  (11037) BRKR /

Comments